Use of S-nitrosothiol signaling to treat disordered control of breathing
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 7, 2008
Grant Date -
Nov 11, 2004
app pub date -
Aug 12, 2002
filing date -
Aug 20, 2001
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention is directed to a method of treating disordered control of breathing including the treatment of apnea and hypoventilation associated with congenital or acquired brain stem abnormalities. Specifically the invention is directed to treating disordered control of breathing by administering an S-nitrosylating agent selected from the group consisting of ethyl nitrite, glutathione, nitric oxide, S-nitrosocysteine, S-nitrosoglutathione, S-nitro-N-acetyl cysteine. As shown in FIG. 1C the ability of endogenous SNO.sub.g to increase V.sub.E in freely behaving, conscious rates using whole-body plethysmography revealed that CSNO, GSNO and CGSNO (1 nmol each) caused equivalent increases in V.sub.E, whereas D-CSNO had no effect (left bar graph is the equivalent increases in V.sub.E, whereas D-CSNO had no effect (left bar graph is the control whereas the right bar represents administration of the respective SNO).
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully